InvestDashboard.com



Nexvet Biopharma Public Limited Company (NVET)



$2.61
52 Week Low
$6.6
2017-04-28 14:02:39 MDT
$6.76
52 Week High

Basic Info

Healthcare
Sector
Biotechnology
Industry
Nasdaq
Stock Exchange
Ireland
Country

Market Cap: $77,800,000Micro Cap (Less than $200M)
Analyst Recommendation:3Analysts say: Neutral. (1=Strong Buy, 5=Strong Sell)
Beta: N/A Unknown Beta. A beta of 1 means that stock will go up or down at the same rate as the S&P 500 index.

Fundamentals

ForwardPE: Unknown
5 Yr Est Growth: Unknown
Yield: 0.00%
PEG-Y Ratio: N/A
Unknown PEG-Y ratio

Technicals

% Above 50 DayMA: 49.66%
% Above 200 DayMA: 66.67%
NVET Performance 52 Weeks: 120.67%
S&P 500 Performance 52 Weeks: 13.50%
Uptrend is still intact: NVET is above both 50 and 200 day Moving Averages. There is hope because 50 Day MA is still above 200 Day MA. Stock is closer to 52 Week High than 52 Week Low.
NVET outperforming S&P 500 by 107.17% the last 52 Weeks.

Profile


More Valuation

Price To Book: 2.97
Great Value. Low Price to Book means better value.
EV to EBITDA: -2.99
Unknown EV to EBITDA ratio

More Info

Field Value Average Comments
% Held By Insiders48.53% 17.28%Held by greater than average Insiders. Insiders can sway stock price. Watch insider buying and selling.
% Held By Institutions31.40% 62.07%Institutional percentage lower than average. Institutions may not have conviction in stock. Or is this a chance for institutions to invest more and boost price?
Short % Of Float2.28% 07.02% Shorted percentage less than average percent. Is stock loved? Do traders and investors believe in the stock?
Debt to EquityN/A 1.08Unknown.
Profit Margin %N/A-00.18%Unknown.
Operating Margin %N/A-05.28%Unknown.
Return on Equity %-57.67%-08.79% Return on Equity less than average percent. Stock can do better than this?
Return on Assets %-31.92%-01.29% Return on Assets less than average percent. Stock can do better than this?
Revenue Per Employee $N/A $883,096.70Unknown.
Price to Cash 3.79 5.52 Lower than average Price to Cash. Meaning that the company has a higher percentage of cash as a percent of price. Cash can be good to cushion company during hard times, and as a potential source for buyouts or investments. However, some activists want the cash to be used by a company to buy its own stock, or to increase their dividend, or to invest the money.
CPEGY Ratio N/A 2.26Unknown.

Quick Thoughts

PROS:
  1. Stock is Above Short Term 50DMA: 49.66%

  2. Stock is Above Long Term 200DMA: 66.67%

  3. Stock outperforming S&P 500 over last 52 weeks: 107.17%

  4. Price to Cash Ratio (3.79) is less than average. Good. Company has more cash as percentage of price than other companies.

  5. Price to Book is under 5: 2.97

  6. Shorted less than average: 2.28%

CONS:
  1. Return on Equity is negative: -57.67%

  2. Return on Assets is negative: -31.92%


Headlines


Stock Chart


InvestDashboard.com NVET: Nexvet Biopharma Public Limited Company

This page updated Thu Feb 1 22:00:01 MST 2018.